Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy

British Journal of Cancer

Volumn 91, Issue 7, 2004, Pages 1239-1244

  Allal, A S ^a   Gervaz, P ^a   Brundler M A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Chemotherapy; Cyclin D; Cyclin E; P21; Predictive; Radiotherapy

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN E; FLUOROURACIL; MITOMYCIN; PROTEIN P21; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; TUMOR MARKER;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM BIOPSY; ANUS TUMOR; CARCINOMA; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 6944253628     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602111     Document Type: Article

References (35)

1. Allal AS, Alonso-Pentzke L, Remadi S (1998) Apparent lack of prognostic value of MIB-1 index in anal carcinomas treated by radiotherapy. Br J Cancer 77: 1333-1336
2. Allal AS, Mermillod B, Roth AD, Marti MC, Kurtz JM (1997) Impact of treatment factors on local control in T2-3 anal carcinoma treated by radiotherapy with or without chemotherapy. Cancer 79: 2329-2335
3. Allal AS, Waelchli L, Bründler M-A (2002) Prognostic value of apoptosis-regulating proteins in anal carcinoma patients. Radiother Oncol 64(S1): 152
4. Anton RC, Coffey DM, Gondo MM, Stephenson MA, Brown RW, Cagle PT (2000) The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung. Mod Pathol 13: 1167-1172
5. Anttila MA, Kosma V-M, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjanen K (1999) p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79: 1870-1878
6. Bartek J, Lukas J (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett (2001); 490: 117-122
7. Bartkova J, Lukas J, Bartek J (1997) Aberrations of the G1- and G1/S-regulating genes in human cancer. Prog Cell Cycle Res 3: 211-220
8. Begg AC, Hofland I, Moonen L, Bartelink H, Schraub S, Bontemps P, Le Fur R, Van Den Bogaert W, Caspers R, Van Glabbeke M (1990) The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys 19: 1449-1453
9. Clarke B, Chetty R (2001) Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 82: 238-246
10. Cummings BJ, Keane TJ, O'Sullivan B, Wong CS, Catton CN (1991) Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 21: 1115-1125
11. Donnellan R, Kleinschmidt I, Chetty R (2001) Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol 32: 89-94
12. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
13. Elledge SJ, Harper JW (1994) Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852
14. Ferreri AJ, Ponzoni M, Pruneri G, Freschi M, Rossi R, Dell'Oro S, Baldini L, Buffa R, Carboni N, Villa E, Viale G (2001) Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int J Cancer 94: 599-604
15. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, Goldman S, Svensson C, Adami HO, Melbye M (1997) Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337: 1350-1358
16. Galloway DA, McDougall JK (1996) The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 7: 309-315
17. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
18. WAF1 is an indicator of malignant behaviour in anal carcinomas. Histopathology 39: 43-49
19. Kato J (1999) Induction of S phase by G1 regulatory factors. Front Biosci 4: 787-792
20. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K, Crum CP (2001) Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 25: 884-891
21. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347: 1566-1575
22. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, Kikui M, Ohno A, Fukuoka M, Kawase I (1997) p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 3: 1831-1835
23. Lochrin CA, Wilson GD, McNally NJ, Dische S, Saunders MI (1992) Tumor cell kinetics, local tumor control and accelerated radiotherapy: a preliminary report. Int J Radiat Oncol Biol Phys 24: 87-91
24. Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE, Serve H (2001) Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 61: 647-653
25. Nishimura G, Tsukuda M, Zhou LX, Furukawa S, Baba Y (1998) Cyclin D1 expression as a prognostic factor in advanced hypopharyngeal carcinoma. J Laryngol Otol 112: 552-555
26. Pagano M, Theodoras AM, Tam SW, Draetta G (1994) Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8: 1627-1639
27. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2003) p21(WAF1) expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 56: 214-220
28. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225
29. Resnitzky D, Gossen M, Bujard H, Reed S (1994) Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 4: 1669-1679
30. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163
31. WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90: 1072-1079
32. Touboul E, Schlienger M, Buffat L, Lefkopoulos D, Pène F, Parc R, Tiret E (1994) Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 73: 1570-1579
33. UKCCCR Anal Cancer Trial Working Party: Epidermoid anal cancer (1996) Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5 fluorouracil and mitomycin C. Lancet 348: 1049-1054
34. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T, Monden M (1997) p21 (Waf1/cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 107: 684-691
35. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deissroth AB (1995) High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1: 1051-1057